From Nasdaq.:

Artificial intelligence (AI) is revolutionizing industries beyond Big Tech, impacting healthcare significantly. Goldman Sachs analysts predict AI advancements will boost U.S. GDP by 1.3%. Nvidia’s investment in healthcare showcases the importance of AI in drug discovery. For investors seeking AI-related drug stocks, Abcellera Biologics, Schrodinger, and Absci are top picks. ABCL, SDGR, and ABSI have unique technological platforms and strong potential for growth. With a diverse pipeline and strategic partnerships, these companies are poised for success in the evolving healthcare landscape.



Read more at Nasdaq.: 3 AI-Driven Drug Stocks to Buy Before They Breakout